Researchers from The Medical Center of Central Massachusettson Wednesday presented animal data demonstrating theefficacy of Cambridge NeuroScience Inc.'s neuroprotectivecompound.

Nerve cell death following a stroke is triggered by excessiveglutamate released from damaged nerve terminals. The excessglutamate, in turn, stimulates the massive entry of calcium intonerve cells, resulting in cell death and brain damage. CNS-1102is the company's lead NMDA ion channel blocker to prevent theinward flow of calcium.

Sixteen rats in an experimental stroke model were treated witheither CNS-1102 or a placebo. Three hours after the stroke, thearea of ischemia in rats given the drug was 6.6 percent of thetotal section area, compared with 31.5 percent in rats given aplacebo, according to the researchers.

Postmortem, the ischemic area in treated animals was 14.4percent, vs. 33 percent in the placebo rats.

Based on the data, the Cambridge, Mass., company(NASDAQ:CNSI) said it plans to begin Phase I trials of thechannel blocker by the end of this year. The company's stockrose $1.25 to $7.75.

(c) 1997 American Health Consultants. All rights reserved.